| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 0.97 | 81.8% | 90.8% |
| Total Income | 0.97 | 81.8% | 90.8% |
| Expenditure | 62.99 | 6.8% | 45.6% |
| PBT | -59.73 | 0.7% | |
| Net Profit | -59.73 | 0.5% | 103.4% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.85 | 0.0% | 57.4% |
EyePoint Reports Q3 2025 Financial Results; Revenue at $1.0 million
04 May 2026 · 4 May, 8:01 am
Summary
EyePoint Pharmaceuticals announced its financial results for the third quarter ended September 30, 2025. Total net revenue was $1.0 million, a decrease from $10.5 million in the same quarter of the previous year. The decrease in revenue was primarily due to the recognition of remaining deferred revenue related to the company’s 2023 agreement for the license of YUTIQ® product rights. The net loss for the quarter was $59.7 million, or ($0.85) per share, compared to a net loss of $29.4 million, or ($0.54) per share, for the corresponding period in 2024. The company expects its cash, cash equivalents, and marketable securities will fund operations into the fourth quarter of 2027.
Key Highlights
- 1
EyePoint Pharmaceuticals reported total net revenue of $1.0 million for the third quarter ended September 30, 2025, compared to $10.5 million for the quarter ended September 30, 2024.
- 2
License and royalties revenue totaled $0.4 million in Q3 2025, a decrease from $9.9 million in the corresponding period in 2024.
- 3
Operating expenses for the third quarter ended September 30, 2025, totaled $63.0 million, compared to $43.3 million in the prior year period.
- 4
The company's net loss was $59.7 million, or ($0.85) per share, compared to a net loss of $29.4 million, or ($0.54) per share, for the corresponding period in 2024.
- 5
Cash, cash equivalents, and marketable securities totaled $204 million as of September 30, 2025, compared to $371 million as of December 31, 2024.
- 6
EyePoint expects its cash, cash equivalents, and marketable securities as of September 30, 2025, along with the net proceeds from the October equity financing, will enable the Company to fund operations into the fourth quarter of 2027.
- 7
Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD are fully enrolled and on track for data readout beginning in mid-2026.
Management Comments
Jay S. Duker
M.D.
“We solidified our clinical leadership in sustained release therapy for retinal disease, with DURAVYU now in Phase 3 development in the two largest markets, wet AMD and DME,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “With topline data from our LUGANO trial expected in mid-2026 and LUCIA to closely follow, we believe we are well-positioned for DURAVYU to be first to file and first to market among all investigational sustained release programs in this indication, positioning DURAVYU at the forefront of innovation.” Dr. Duker continued, “With the initiation of our pivotal Phase 3 program, DURAVYU is the only TKI in development for DME, which is a three-billion-dollar market and growing. Our recent data demonstrating DURAVYU’s multi-target MOA further underscores our confidence as we move forward in this indication. Based on these findings, along with our compelling Phase 2 VERONA data, we believe that DURAVYU is uniquely positioned to potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME as a sustained delivery therapy. We look forward to an eventful 2026 as our established regulatory pathway, exceptional execution, and strong cash position have us well positioned for key data readouts beginning mid-year.”
Informational and educational content only. Not investment advice.